Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 19 (16), 1817-1819

Brexpiprazole: A Step Forward for Precision Medicine in Resistant Depression

Affiliations

Brexpiprazole: A Step Forward for Precision Medicine in Resistant Depression

Alessandro Serretti. Expert Opin Pharmacother.

Abstract

Resistant depression is still a common and burdensome issue and there is an urgent need for new and effective adjunctive treatments. Areas covered: In this paper, the author discusses the background, trial design, results and implications of a recent study (NCT02196506, Sirius study) which confirmed the possible benefit of brexpiprazole as adjunctive treatment in depressed subjects with inadequate benefit from first line treatments. As secondary aims, the study confirmed the effects in subjects with minimal benefit from standard treatments and in subjects with anxious distress. Despite some reported side effects such as akathisia, restlessness, and increased weight, the treatment was well tolerated. Expert opinion: The unique pharmacodynamic profile of brexpiprazole, in terms of reduced dopamine intrinsic stimulation and a range of other more anxiolytic receptor effects, suggests that brexpiprazole should be preferred in specific subpopulations, particularly where a more sedative profile is needed. Indeed, this study suggests another step in the direction of precision medicine.

Keywords: Antipsychotics; depression; precision medicine; psychiatry; psychopharmacology.

Similar articles

See all similar articles

MeSH terms

LinkOut - more resources

Feedback